Literature DB >> 9255687

Radiofrequency catheter ablation of sustained monomorphic ventricular tachycardia in hypertrophic cardiomyopathy.

L M Rodriguez1, J L Smeets, C Timmermans, D Blommaert, J M van Dantzig, E B de Muinck, H J Wellens.   

Abstract

INTRODUCTION: Incessant monomorphic ventricular tachycardia (VT) with a right bundle branch block morphology and a northwest axis is a rare arrhythmic complication in a patient with hypertrophic cardiomyopathy and apical left ventricular aneurysm. METHODS AND
RESULTS: The origin of this VT was localized using the following criteria: the presence of entrainment without fusion, equal intervals from the stimulus to the beginning of the QRS complex and from the electrogram to the QRS complex during VT, and the first postpacing interval identical to the tachycardia cycle length. Radiofrequency energy applied to the septoapical part of the apical left ventricular aneurysm terminated the tachycardia within 2 seconds.
CONCLUSION: Using criteria to guide radiofrequency (RF) ablation of VT in patients with coronary artery disease, an incessant monomorphic VT in a patient with hypertrophic cardiomyopathy was successfully ablated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255687     DOI: 10.1111/j.1540-8167.1997.tb00838.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  3 in total

1.  [Guidelines for catheter ablation].

Authors:  Karl-Heinz Kuck; Sabine Ernst; Uwe Dorwarth; Ellen Hoffmann; Heinz Pitschner; Jürgen Tebbenjohanns; Hans Kottkamp
Journal:  Clin Res Cardiol       Date:  2007-11       Impact factor: 5.460

2.  Long-term Outcomes of Ventricular Tachycardia Ablation in Different Types of Structural Heart Disease.

Authors:  Jackson J Liang; Pasquale Santangeli; David J Callans
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-12-01

3.  Mid-septal hypertrophy and apical ballooning; potential mechanism of ventricular tachycardia storm in patients with hypertrophic cardiomyopathy.

Authors:  Eui-Seock Hwang; Hui-Nam Pak
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.